AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
arsenic trioxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 244 | 1327-53-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML) retinoic acid receptor (RAR)-alpha.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 7.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.76 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 37 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FLT4,GRK2,GRK3,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 85 | |||
| kinase-selectivity-class | ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,GRK2,GSK3B,HIPK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PIK3CB,PIK3CG,PRKDC,STK33,TEK,TGFBR1,TTK,UHMK1 | 20 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 14, 2019 | EMA | ACCORD HEALTHCARE SLU | |
| Sept. 25, 2000 | FDA | CEPHALON |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Differentiation syndrome | 760.99 | 13.56 | 133 | 10854 | 1198 | 90616262 |
| Electrocardiogram QT prolonged | 203.10 | 13.56 | 120 | 10867 | 72336 | 90545124 |
| Febrile neutropenia | 96.38 | 13.56 | 107 | 10880 | 158242 | 90459218 |
| Hepatic function abnormal | 87.92 | 13.56 | 60 | 10927 | 46228 | 90571232 |
| Intracranial pressure increased | 54.37 | 13.56 | 23 | 10964 | 6788 | 90610672 |
| White blood cell count decreased | 50.30 | 13.56 | 80 | 10907 | 167029 | 90450431 |
| Platelet count decreased | 44.59 | 13.56 | 68 | 10919 | 136901 | 90480559 |
| Alanine aminotransferase increased | 43.20 | 13.56 | 62 | 10925 | 118276 | 90499184 |
| Idiopathic intracranial hypertension | 42.16 | 13.56 | 16 | 10971 | 3565 | 90613895 |
| Aspartate aminotransferase increased | 42.15 | 13.56 | 57 | 10930 | 102880 | 90514580 |
| Disseminated intravascular coagulation | 38.71 | 13.56 | 27 | 10960 | 21511 | 90595949 |
| Lower respiratory tract infection fungal | 35.91 | 13.56 | 8 | 10979 | 266 | 90617194 |
| Leukaemia recurrent | 34.56 | 13.56 | 11 | 10976 | 1456 | 90616004 |
| Neutrophil count decreased | 32.98 | 13.56 | 42 | 10945 | 71490 | 90545970 |
| Pericardial effusion | 31.64 | 13.56 | 30 | 10957 | 36803 | 90580657 |
| Leukocytosis | 30.03 | 13.56 | 27 | 10960 | 30963 | 90586497 |
| Haematopoietic neoplasm | 29.22 | 13.56 | 5 | 10982 | 39 | 90617421 |
| Myelosuppression | 28.80 | 13.56 | 34 | 10953 | 53557 | 90563903 |
| Acute myeloid leukaemia | 28.35 | 13.56 | 22 | 10965 | 20618 | 90596842 |
| Systemic lupus erythematosus | 28.08 | 13.56 | 5 | 10982 | 361891 | 90255569 |
| Contraindicated product administered | 23.62 | 13.56 | 5 | 10982 | 320134 | 90297326 |
| Bone marrow necrosis | 23.55 | 13.56 | 5 | 10982 | 132 | 90617328 |
| Drug intolerance | 22.76 | 13.56 | 13 | 10974 | 447578 | 90169882 |
| Respiratory failure | 21.97 | 13.56 | 46 | 10941 | 118372 | 90499088 |
| Discomfort | 20.83 | 13.56 | 4 | 10983 | 274331 | 90343129 |
| Pyrexia | 20.77 | 13.56 | 144 | 10843 | 660341 | 89957119 |
| Gamma-glutamyltransferase increased | 20.26 | 13.56 | 24 | 10963 | 37928 | 90579532 |
| Gambling | 20.25 | 13.56 | 5 | 10982 | 261 | 90617199 |
| Blood lactate dehydrogenase increased | 20.16 | 13.56 | 20 | 10967 | 25912 | 90591548 |
| Wound | 19.90 | 13.56 | 6 | 10981 | 302974 | 90314486 |
| Chromosomal deletion | 18.94 | 13.56 | 4 | 10983 | 103 | 90617357 |
| VIth nerve paralysis | 18.17 | 13.56 | 6 | 10981 | 892 | 90616568 |
| Laryngeal inflammation | 17.84 | 13.56 | 4 | 10983 | 137 | 90617323 |
| Long QT syndrome | 17.70 | 13.56 | 9 | 10978 | 4028 | 90613432 |
| General physical health deterioration | 17.09 | 13.56 | 11 | 10976 | 355104 | 90262356 |
| Sweat gland tumour | 17.05 | 13.56 | 4 | 10983 | 168 | 90617292 |
| Blast cell count increased | 16.85 | 13.56 | 5 | 10982 | 524 | 90616936 |
| Infusion related reaction | 16.18 | 13.56 | 16 | 10971 | 416764 | 90200696 |
| Ventricular extrasystoles | 15.80 | 13.56 | 13 | 10974 | 13237 | 90604223 |
| Therapeutic product effect decreased | 15.69 | 13.56 | 7 | 10980 | 277564 | 90339896 |
| Chills | 15.54 | 13.56 | 43 | 10944 | 131938 | 90485522 |
| Arthropathy | 15.48 | 13.56 | 13 | 10974 | 366229 | 90251231 |
| Oedematous pancreatitis | 14.90 | 13.56 | 5 | 10982 | 780 | 90616680 |
| Leukostasis syndrome | 14.57 | 13.56 | 3 | 10984 | 68 | 90617392 |
| Hypoxia | 14.46 | 13.56 | 29 | 10958 | 72370 | 90545090 |
| Swelling | 14.18 | 13.56 | 18 | 10969 | 419040 | 90198420 |
| Blood cholesterol increased | 13.87 | 13.56 | 4 | 10983 | 208008 | 90409452 |
| Hyperaesthesia | 13.81 | 13.56 | 11 | 10976 | 10691 | 90606769 |
| Gastrointestinal disorder | 13.70 | 13.56 | 7 | 10980 | 256680 | 90360780 |
| Abdominal discomfort | 13.70 | 13.56 | 23 | 10964 | 477305 | 90140155 |
| Pleural effusion | 13.70 | 13.56 | 37 | 10950 | 111954 | 90505506 |
| Induced labour | 13.68 | 13.56 | 5 | 10982 | 1003 | 90616457 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Differentiation syndrome | 695.21 | 17.15 | 136 | 7034 | 1677 | 42612488 |
| Electrocardiogram QT prolonged | 303.84 | 17.15 | 152 | 7018 | 47793 | 42566372 |
| Idiopathic intracranial hypertension | 125.94 | 17.15 | 29 | 7141 | 801 | 42613364 |
| Hyperleukocytosis | 105.78 | 17.15 | 32 | 7138 | 2576 | 42611589 |
| Febrile neutropenia | 74.65 | 17.15 | 121 | 7049 | 185582 | 42428583 |
| Hepatic function abnormal | 55.41 | 17.15 | 55 | 7115 | 51512 | 42562653 |
| Myelosuppression | 50.74 | 17.15 | 47 | 7123 | 40414 | 42573751 |
| Disseminated intravascular coagulation | 39.49 | 17.15 | 33 | 7137 | 24761 | 42589404 |
| Acute myeloid leukaemia | 38.32 | 17.15 | 31 | 7139 | 22225 | 42591940 |
| Hypokalaemia | 37.62 | 17.15 | 53 | 7117 | 71668 | 42542497 |
| Alanine aminotransferase increased | 34.58 | 17.15 | 57 | 7113 | 88349 | 42525816 |
| Haematopoietic neoplasm | 32.65 | 17.15 | 6 | 7164 | 51 | 42614114 |
| Platelet count decreased | 30.43 | 17.15 | 70 | 7100 | 138511 | 42475654 |
| Bone marrow necrosis | 27.56 | 17.15 | 7 | 7163 | 294 | 42613871 |
| White blood cell count increased | 23.15 | 17.15 | 33 | 7137 | 45054 | 42569111 |
| Pericardial effusion | 20.57 | 17.15 | 25 | 7145 | 29250 | 42584915 |
| Periarthritis | 20.56 | 17.15 | 8 | 7162 | 1372 | 42612793 |
| Septic embolus | 20.42 | 17.15 | 8 | 7162 | 1397 | 42612768 |
| Aspartate aminotransferase increased | 20.36 | 17.15 | 42 | 7128 | 77121 | 42537044 |
| Extremity necrosis | 19.64 | 17.15 | 9 | 7161 | 2310 | 42611855 |
| Blood lactate dehydrogenase increased | 19.52 | 17.15 | 23 | 7147 | 26058 | 42588107 |
| Pneumonia | 19.25 | 17.15 | 129 | 7041 | 422020 | 42192145 |
| Testicular haemorrhage | 18.80 | 17.15 | 5 | 7165 | 252 | 42613913 |
| Leukaemia recurrent | 18.18 | 17.15 | 8 | 7162 | 1868 | 42612297 |
| Pericarditis | 17.58 | 17.15 | 16 | 7154 | 13428 | 42600737 |
| Jugular vein thrombosis | 17.41 | 17.15 | 8 | 7162 | 2066 | 42612099 |
| Drug ineffective | 17.18 | 17.15 | 52 | 7118 | 630145 | 41984020 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Differentiation syndrome | 1395.78 | 13.41 | 259 | 15703 | 2785 | 110570552 |
| Electrocardiogram QT prolonged | 398.81 | 13.41 | 228 | 15734 | 108732 | 110464605 |
| Febrile neutropenia | 169.16 | 13.41 | 218 | 15744 | 316549 | 110256788 |
| Idiopathic intracranial hypertension | 147.84 | 13.41 | 44 | 15918 | 3908 | 110569429 |
| Hepatic function abnormal | 147.71 | 13.41 | 114 | 15848 | 89181 | 110484156 |
| Hyperleukocytosis | 123.06 | 13.41 | 37 | 15925 | 3402 | 110569935 |
| Myelodysplastic syndrome transformation | 98.42 | 13.41 | 23 | 15939 | 794 | 110572543 |
| Platelet count decreased | 82.14 | 13.41 | 131 | 15831 | 230312 | 110343025 |
| Myelosuppression | 75.41 | 13.41 | 80 | 15882 | 94260 | 110479077 |
| Acute myeloid leukaemia | 74.92 | 13.41 | 54 | 15908 | 38056 | 110535281 |
| Disseminated intravascular coagulation | 73.27 | 13.41 | 55 | 15907 | 41231 | 110532106 |
| White blood cell count decreased | 69.17 | 13.41 | 121 | 15841 | 229269 | 110344068 |
| Alanine aminotransferase increased | 68.97 | 13.41 | 107 | 15855 | 183666 | 110389671 |
| Haematopoietic neoplasm | 62.46 | 13.41 | 11 | 15951 | 85 | 110573252 |
| Aspartate aminotransferase increased | 55.68 | 13.41 | 90 | 15872 | 159846 | 110413491 |
| Bone marrow necrosis | 51.21 | 13.41 | 12 | 15950 | 419 | 110572918 |
| Leukaemia recurrent | 45.13 | 13.41 | 17 | 15945 | 3114 | 110570223 |
| Pericardial effusion | 44.79 | 13.41 | 48 | 15914 | 57169 | 110516168 |
| Leukocytosis | 41.85 | 13.41 | 45 | 15917 | 53783 | 110519554 |
| Blood lactate dehydrogenase increased | 39.74 | 13.41 | 40 | 15922 | 44294 | 110529043 |
| Neutrophil count decreased | 37.98 | 13.41 | 65 | 15897 | 120876 | 110452461 |
| Intracranial pressure increased | 35.67 | 13.41 | 21 | 15941 | 10514 | 110562823 |
| Pneumonia | 35.52 | 13.41 | 232 | 15730 | 876482 | 109696855 |
| Hypokalaemia | 30.96 | 13.41 | 76 | 15886 | 182372 | 110390965 |
| White blood cell count increased | 30.34 | 13.41 | 52 | 15910 | 96790 | 110476547 |
| Pyrexia | 26.24 | 13.41 | 220 | 15742 | 898045 | 109675292 |
| Pleural effusion | 25.99 | 13.41 | 70 | 15892 | 177639 | 110395698 |
| Lower respiratory tract infection fungal | 25.48 | 13.41 | 8 | 15954 | 849 | 110572488 |
| Central nervous system leukaemia | 23.94 | 13.41 | 7 | 15955 | 584 | 110572753 |
| Treatment failure | 20.85 | 13.41 | 7 | 15955 | 277227 | 110296110 |
| Sepsis | 20.83 | 13.41 | 98 | 15864 | 327248 | 110246089 |
| Blood alkaline phosphatase increased | 20.80 | 13.41 | 37 | 15925 | 70898 | 110502439 |
| Gamma-glutamyltransferase increased | 20.63 | 13.41 | 34 | 15928 | 61275 | 110512062 |
| Lower respiratory tract infection | 20.38 | 13.41 | 5 | 15957 | 243101 | 110330236 |
| Testicular haemorrhage | 19.63 | 13.41 | 5 | 15957 | 248 | 110573089 |
| Ulnar neuritis | 19.63 | 13.41 | 3 | 15959 | 8 | 110573329 |
| Drug intolerance | 19.46 | 13.41 | 18 | 15944 | 406494 | 110166843 |
| Therapeutic reaction time decreased | 19.13 | 13.41 | 11 | 15951 | 5268 | 110568069 |
| Long QT syndrome | 18.53 | 13.41 | 12 | 15950 | 7106 | 110566231 |
| Pancytopenia | 18.19 | 13.41 | 69 | 15893 | 209544 | 110363793 |
| Systemic lupus erythematosus | 18.14 | 13.41 | 7 | 15955 | 254331 | 110319006 |
| Septic embolus | 17.71 | 13.41 | 8 | 15954 | 2318 | 110571019 |
| Wound | 17.48 | 13.41 | 6 | 15956 | 234431 | 110338906 |
| Contraindicated product administered | 17.43 | 13.41 | 7 | 15955 | 248260 | 110325077 |
| Staphylococcal infection | 17.40 | 13.41 | 34 | 15928 | 69910 | 110503427 |
| Blood cholesterol increased | 17.13 | 13.41 | 3 | 15959 | 184782 | 110388555 |
| Bone marrow failure | 16.73 | 13.41 | 30 | 15932 | 57818 | 110515519 |
| Extremity necrosis | 16.73 | 13.41 | 9 | 15953 | 3793 | 110569544 |
| Drug abuse | 16.19 | 13.41 | 3 | 15959 | 177408 | 110395929 |
| Chromosomal deletion | 16.15 | 13.41 | 4 | 15958 | 177 | 110573160 |
| Protein total decreased | 16.04 | 13.41 | 13 | 15949 | 10877 | 110562460 |
| Ventricular extrasystoles | 15.99 | 13.41 | 18 | 15944 | 22623 | 110550714 |
| Acute promyelocytic leukaemia | 15.97 | 13.41 | 7 | 15955 | 1889 | 110571448 |
| Respiratory failure | 14.82 | 13.41 | 66 | 15896 | 215266 | 110358071 |
| Arthropathy | 14.64 | 13.41 | 12 | 15950 | 287510 | 110285827 |
| Hypomagnesaemia | 14.60 | 13.41 | 29 | 15933 | 60341 | 110512996 |
| Hyperaesthesia | 14.52 | 13.41 | 14 | 15948 | 14713 | 110558624 |
| Hypoxia | 14.14 | 13.41 | 46 | 15916 | 129469 | 110443868 |
| Infusion related reaction | 13.83 | 13.41 | 21 | 15941 | 381141 | 110192196 |
| Neutropenia | 13.82 | 13.41 | 97 | 15865 | 374523 | 110198814 |
| Laryngeal inflammation | 13.69 | 13.41 | 4 | 15958 | 333 | 110573004 |
| Blast cell count increased | 13.64 | 13.41 | 6 | 15956 | 1631 | 110571706 |
| Oedematous pancreatitis | 13.59 | 13.41 | 6 | 15956 | 1648 | 110571689 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XX27 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Related Drugs by ATC class:
L01XX Other antineoplastic agents 33 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute promyelocytic leukemia, FAB M3 | indication | 110004001 | |
| Acute myelomonocytic leukemia, FAB M4 | indication | 110005000 | |
| Myelodysplastic syndrome | off-label use | 109995007 | |
| Hyperkalemia | contraindication | 14140009 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Chronic heart failure | contraindication | 48447003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Congenital long QT syndrome | contraindication | 442917000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thioredoxin reductase 1, cytoplasmic | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.82 | WOMBAT-PK | |||||
| Somatostatin receptor type 2 | GPCR | Kd | 4.60 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D02106 | KEGG_DRUG |
| 18330 | RXNORM |
| C0052416 | UMLSCUI |
| CHEBI:30621 | CHEBI |
| CHEMBL5483015 | ChEMBL_ID |
| DB01169 | DRUGBANK_ID |
| D000077237 | MESH_DESCRIPTOR_UI |
| 14888 | PUBCHEM_CID |
| S7V92P67HO | UNII |
| 15787 | MMSL |
| 40534 | MMSL |
| 71831 | MMSL |
| d04720 | MMSL |
| 4021238 | VANDF |
| 007172 | NDDF |
| 400907001 | SNOMEDCT_US |
| 72251000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3498 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 28 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-600 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 23155-869 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 23155-869 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 23155-870 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 23155-870 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-226 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 31 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-227 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 31 sections |
| Sinus HP | HUMAN OTC DRUG LABEL | 11 | 44911-0629 | LIQUID | 30 [hp_X] | ORAL | unapproved drug other | 9 sections |
| Jointox BB | HUMAN OTC DRUG LABEL | 17 | 44911-0642 | LIQUID | 30 [hp_C] | ORAL | unapproved drug other | 9 sections |
| Arsenic trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49315-005 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 1 sections |
| Arsenic trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49315-007 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 1 sections |
| ARSENIC TRIOXIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-438 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| 7 Heavy Metal Detox | HUMAN OTC DRUG LABEL | 61 | 55146-007 | LIQUID | 12 [hp_X] | ORAL | unapproved homeopathic | 9 sections |
| 1 Detoxification | HUMAN OTC DRUG LABEL | 81 | 55146-011 | LIQUID | 12 [hp_X] | ORAL | unapproved homeopathic | 9 sections |
| ARSENIC TRIOXIDE | Human Prescription Drug Label | 1 | 55150-366 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 28 sections |
| Hay Fever | HUMAN OTC DRUG LABEL | 55 | 55714-2562 | LIQUID | 15 [hp_X] | ORAL | unapproved homeopathic | 10 sections |
| BronCare | HUMAN OTC DRUG LABEL | 29 | 55714-4840 | PELLET | 15 [hp_X] | ORAL | unapproved homeopathic | 10 sections |
| Homeopathic Moon drops | HUMAN OTC DRUG LABEL | 9 | 57556-008 | LOZENGE | 30 [hp_X] | ORAL | unapproved drug other | 6 sections |
| Homeopathic Moon drops | HUMAN OTC DRUG LABEL | 9 | 57556-008 | LOZENGE | 30 [hp_X] | ORAL | unapproved drug other | 6 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-637 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 29 sections |
| Trisenox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-601 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | NDA | 23 sections |
| Emvita 6 | HUMAN OTC DRUG LABEL | 5 | 66343-018 | LIQUID | 18 [hp_M] | ORAL | UNAPPROVED HOMEOPATHIC | 10 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 68083-462 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 28 sections |
| Arsenic Trioxide | Human Prescription Drug Label | 1 | 68083-535 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 28 sections |
| Arsenic trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68382-997 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 26 sections |
| ARSENIC TRIOXIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-720 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 26 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1483 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 27 sections |
| Arsenic Trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1658 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 27 sections |
| Arsenic trioxide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1610 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 26 sections |